Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects
Brief Summary: To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe, Drug: Niaspan, Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Procedure: Percutaneous transluminal angioplasty (PTA) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Drug: Placebo Niaspan, Drug: Placebo Ezetimibe, Procedure: Percutaneous transluminal angioplasty (PTA) | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Niaspan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo Niaspan; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Ezetimibe; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Percutaneous transluminal angioplasty (PTA); Assigned to Arm(s): 1, 2
B: Arm Label: LZ group; Type: EXPERIMENTAL; Interventions: Drug: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe] | Arm Label: L group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lipitor (Atorvastatin) monotherapy | Intervention Type: DRUG; Name: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]; Assigned to Arm(s): LZ group | Intervention Type: DRUG; Name: Lipitor (Atorvastatin) monotherapy; Assigned to Arm(s): L group
C: Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Drug: Atorvastatin, Drug: Ezetimibe, Other: Diet Only | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Atorvastatin, Drug: Ezetimibe, Other: Diet Only | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Evolocumab, Placebo | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Evolocumab, Placebo | Intervention Type: OTHER; Name: Diet Only; Assigned to Arm(s): Evolocumab, Placebo
D: Arm Label: Atorvastatin + Evacetrapib; Type: EXPERIMENTAL; Interventions: Drug: Evacetrapib, Drug: Atorvastatin, Drug: Placebo | Arm Label: Atorvastatin 80 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Atorvastatin + Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Atorvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Evacetrapib; Assigned to Arm(s): Atorvastatin + Evacetrapib | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin + Evacetrapib, Atorvastatin + Ezetimibe, Atorvastatin 40 mg, Atorvastatin 80 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Atorvastatin + Ezetimibe | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Atorvastatin + Evacetrapib, Atorvastatin + Ezetimibe, Atorvastatin 40 mg, Atorvastatin 80 mg

Answer: C